Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 8/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.36 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.36 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25697 | 1.00 | GRIK1 (0.38) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL716220 | 0.81 | GRIK1 (0.33) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL716221 | 0.81 | GRIK1 (0.33) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL5561691 | 0.80 | CA1 (0.39) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL9805805 | 0.80 | GRIK1 (0.34) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL9805809 | 0.80 | GRIK1 (0.34) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| SCHEMBL5561689 | 0.80 | CA1 (0.39) | GRIK1GRIK2GRIA2GRIA4GRIK3 | |
| Bucrylate SCHEMBL2789798 | 0.80 | TSHR (0.43) | ALDH1A1 | |
| SCHEMBL360118 | 0.77 | KDM1A (0.38) | GRIK1 | |
| SCHEMBL360119 | 0.77 | KDM1A (0.38) | GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116285710-B | Instantaneous adhesive and preparation method and application thereof | 永一胶粘(中山)有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116285710-A | Instantaneous adhesive and preparation method and application thereof | 永一胶粘(中山)有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-116159177-A | Adhesive for treating great saphenous vein and preparation method thereof | 浙江伽奈维医疗科技有限公司 | 2023-05-26 | — | — | CN | claimed |
| CN-109913400-B | Artificial tissue precursors and methods for making same | 四川蓝光英诺生物科技股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115778449-A | Medical adhesive, conveying device and conveying system | 赛微医疗科技(上海)有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20220323368-A1 | ACTIVE SUBSTANCE DELIVERY SYSTEM WITH DELAYED DELIVERY | CAPNOPHARM GMBH (DE) | 2022-10-13 | — | — | US | claimed |
| CN-109735434-B | Artificial tissue precursors and methods of making the same | 四川蓝光英诺生物科技股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| US-20220241213-A1 | DELAYED AND SUSTAINED DELIVERY OF ANTICANCER DRUGS | CAPNOPHARM GMBH (DE) | 2022-08-04 | — | — | US | claimed |
| US-20220226205-A1 | Coated Particles and Their Uses | KENVUE BRANDS LLC | 2022-07-21 | — | — | US | claimed |
| EP-3982918-A1 | DELAYED AND SUSTAINED DELIVERY OF ANTICANCER DRUGS | CAPNOMED GmbH (DE) | 2022-04-20 | — | — | EP | claimed |
| EP-1156812-A1 | MULTIPARTICULATE FORMULATION | ISIS PHARMACEUTICALS, INC. (US) | 2001-11-28 | — | — | EP | claimed |
| WO-2000050050-A1 | MULTIPARTICULATE FORMULATION | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-31 | — | — | WO | claimed |
| CN-1261070-A | Process for preparing isobutyl alpha-cyanoacrylate | ZHU SHIXIN (CN) | 2000-07-26 | — | — | CN | claimed |
| EP-0820300-A1 | CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN | ELAN CORPORATION PLC (IE) | 1998-01-28 | — | — | EP | claimed |
| US-5641515-A | COMPLEX OF INSULIN AND POLYALKYLCYANOACRYLATE OR FREE-INSULIN LOADED POLYALKYLCYANOACRYLATE | ELAN CORPORATION, PLC (IE) | 1997-06-24 | — | — | US | claimed |
| WO-1996031231-A1 | CONTROLLED RELEASE BIODEGRADABLE NANOPARTICLES CONTAINING INSULIN | ELAN CORPORATION, PLC (IE) | 1996-10-10 | — | — | WO | claimed |
| EP-0460806-A2 | Electrophotographic sensitive member | Kinoshita, Koichi (JP) | 1991-12-11 | — | — | EP | claimed |
| US-5063203-A | Anticoagulants, humans | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1991-11-05 | — | — | US | claimed |
| EP-0269598-B1 | THERAPEUTICAL AGENTS AGAINST LEISHMANIOSE | N.V. SOPAR S.A. (BE) | 1991-04-10 | — | — | EP | claimed |
| US-4378213-A | USING AN ACCELERATOR TO PROMOTE HARDENING | MDS PRODUCTS COMPANY, INC. (US) | 1983-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226205-A1 | Coated Particles and Their Uses | CD63, EPCAM, CD44 | GRIK1 3062/4885GRIK2 2619/4885GRIA2 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.